Artelo Biosciences (NASDAQ: ARTL) expands ART27.13 into the $16.3B glaucoma market via a fully funded investigator-sponsored trial while advancing three clinical programs in oncology support, neuropathic pain, and CNS disorders.
Key advantages: positive Phase 2 signals, MHRA guidance for ART12.11, FABP inhibitor Phase 1 safety, European patent protection to 2041, and a $25M equity facility.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.